These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 15005018)

  • 1. Persistent Raynaud's phenomenon after exposure to vinyl chloride monomer: assessment of endothelial damage.
    Fontana L; Marion MJ; Catilina P
    Clin Exp Rheumatol; 2004; 22(1):132-3. PubMed ID: 15005018
    [No Abstract]   [Full Text] [Related]  

  • 2. Acroosteolysis and Raynaud's phenomenon after vinyl chloride exposure.
    Freudiger H; Bounameaux H; Garcia J
    Vasa; 1988; 17(3):216-8. PubMed ID: 3176646
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical and capillaroscopic study of Raynaud's phenomenon in retired patients previously exposed to vinyl chloride monomer].
    Fontana L; Baietto M; Becker F; Catilina P
    J Mal Vasc; 1995; 20(4):268-73. PubMed ID: 8586945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon.
    Kahaleh MB; Osborn I; LeRoy EC
    Ann Intern Med; 1981 Apr; 94(4 pt 1):482-4. PubMed ID: 6782927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelin, vasoconstriction, and endothelial damage in Raynaud's phenomenon.
    Cimminiello C; Milani M; Uberti T; Arpaia G; Perolini S; Bonfardeci G
    Lancet; 1991 Jan; 337(8733):114-5. PubMed ID: 1670699
    [No Abstract]   [Full Text] [Related]  

  • 6. [Endothelin-1 in pathogenesis of Raynaud's syndrome].
    Knapik-Kordecka M; Adamiec R; Ciosek W
    Pol Merkur Lekarski; 2001 Jun; 10(60):424-5. PubMed ID: 11503255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of total-body cold exposure on plasma concentrations of von Willebrand factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus patients with or without Raynaud's phenomenon.
    Matsuda J; Tsukamoto M; Gohchi K; Saitoh N; Miyajima Y; Kazama M
    Acta Haematol; 1992; 88(4):189-93. PubMed ID: 1337960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dermatological aspects of so called vinyl chloride monomer disease.
    Czernielewski A; Kieć-swierczyńska M; Gluszcz M; Woźniak L
    Derm Beruf Umwelt; 1979; 27(4):108-12. PubMed ID: 161529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raynaud's phenomenon in the occupational context.
    Cordeiro RA; Andrade RM
    Rev Assoc Med Bras (1992); 2019; 65(10):1314-1320. PubMed ID: 31721965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raynaud's phenomenon and endothelial dysfunction in end-stage renal disease patients treated with hemodialysis.
    Czupryniak A; Kałuzyńska A; Nowicki M; Wiecek B; Bald E; Owczarek D
    Kidney Blood Press Res; 2005; 28(1):27-31. PubMed ID: 15452382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryoglobulinemia in Raynaud's phenomenon due to vinyl chloride.
    Langauer-Lewowicka H; Dudziak Z; Byczkowska Z; Marks J
    Int Arch Occup Environ Health; 1976 Jan; 36(3):197-207. PubMed ID: 1248884
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon.
    Blann AD; Illingworth K; Jayson MI
    J Rheumatol; 1993 Aug; 20(8):1325-30. PubMed ID: 8230013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. von Willebrand factor activity in primary and in scleroderma-associated Raynaud's phenomenon.
    Cuenca R; Fernadez-Cortijo J; Fonollosa V; Lima J; Simeon CP; Vilardell M; Pico M
    Lancet; 1990 May; 335(8697):1095. PubMed ID: 1970389
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma levels of tissue-type plasminogen activator and von Willebrand factor in patients with Raynaud's phenomenon.
    Marasini B; Cugno M; Agostoni A
    Arthritis Rheum; 1991 Feb; 34(2):255-6. PubMed ID: 1899793
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunological mechanisms in the pathogenesis of vinyl chloride disease.
    Ward AM; Udnoon S; Watkins J; Walker AE; Darke CS
    Br Med J; 1976 Apr; 1(6015):936-8. PubMed ID: 131592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiographic study of digital arteries in workers exposed to vinyl chloride.
    Falappa P; Magnavita N; Bergamaschi A; Colavita N
    Br J Ind Med; 1982 May; 39(2):169-72. PubMed ID: 7066233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
    Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R
    J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical aspects of vinyl chloride disease: skin.
    Walker AE
    Proc R Soc Med; 1976 Apr; 69(4):286-9. PubMed ID: 131318
    [No Abstract]   [Full Text] [Related]  

  • 19. A case of polymyositis with anti-histidyl-t-RNA synthetase (Jo-1) antibody syndrome following extensive vinyl chloride exposure.
    Serratrice J; Granel B; Pache X; Disdier P; De Roux-Serratrice C; Pellissier JF; Weiller PJ
    Clin Rheumatol; 2001; 20(5):379-82. PubMed ID: 11642524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathomechanism of the disease caused by chronic exposure to vinyl chloride (author's transl)].
    Bogdanikowa B
    Przegl Lek; 1980; 37(12):797-801. PubMed ID: 7208967
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.